Rivaroxaban versus Fondaparinux Observational Study for Thromboprophylaxis after Hip or Knee Arthroplasty

Virchow Biotech Private Limited10 个研究点分布在 1 个国家目标入组 100 人开始时间: 2017年1月3日最近更新: 2019年3月19日

试验速览

阶段: 不适用
状态: 招募中
发起方: Virchow Biotech Private Limited
入组人数: 100
试验地点: 10
主要终点: Any Major Bleeding

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

An observation study comparing rivaraxoban with different standard anticoagulants for symptomatic thromboembolism in patients undergoing elective hip or knee replacement surgery

研究设计

研究类型: Observational

入排标准

年龄范围: 18.00 Year(s) 至 65.00 Year(s)（—）
性别: All

入选标准

•Male or Female patients who are undergoing elective hip or knee replacement surgery.

排除标准

•Patients with active bleeding or a high risk of bleeding that contraindicated the use of rivaroxaban ; Other exclusion criteria included conditions preventing bilateral venography, clinically significant liver, cardiac, renal disease, concomitant use of protease inhibitors of the human immunodeficiency virus or fibrinolytic agents, planned intermittent pneumatic compression, requirement of ongoing anticoagulant therapy, and pregnancy or breast-feeding.

结局指标

主要结局

Any Major Bleeding

时间窗: 3 months

次要结局

Any Minor Bleeding(3 months)

研究者

发起方

Virchow Biotech Private Limited

申办方类型

Pharmaceutical industry-Indian

研究点 (10)

Loading locations...

相似试验

招募中

不适用

Rivaroxaban versus Fondaparinux Observational Study for ThromboprophylaxisAfter Hip or Knee Arthroplasty

CTRI/2017/10/010059Virchow Biotech Private Limited

已完成

3 期

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMILeft Ventricular ThrombusST Segment Elevation Myocardial Infarction

NCT05705089Rajaie Cardiovascular Medical and Research Center50

已完成

4 期

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous ThromboembolismVenous Thromboembolism

NCT03266783Ottawa Hospital Research Institute2,760

已完成

4 期

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot StudyVenous Thromboembolism

NCT02559856Ottawa Hospital Research Institute72

已完成

3 期

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus FondaparinuxSuperficial Vein Thrombosis

NCT01499953GWT-TUD GmbH472